The binding of RHAMM to HA is an attractive target, since RHAMM is normally absent or expressed at low levels in homeostatic conditions, but its expression is significantly elevated in the extracellular matrix during tissue stress, response‐to‐injury, and in cancers and inflammation‐based diseases. Here, HMMR is linked to cancer.